Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 19 December 2012 | By Alexander Gaffney, RAC,
The European Medicines Agency (EMA) is preparing to reorganize its operations, processes and offices in 2013, it has announced.
In a statement released on its website on 19 December 2012, the agency said the overhaul will be "focused on increasing the efficiency of its scientific activities and information- and communication-technology operations."
A particular focus will be placed on how it supports the mission of its scientific committees-the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee for Advanced Therapies (CAT) and others-with the aim of better allowing them to reach "high-quality, consistent opinions."
The statement did not make any note of whether the agency currently believed that its scientific committees were of inconsistent quality, and Regulatory Focus has reached out to EMA for clarification and elaboration regarding the changes to be made.
Update: In a statement to Regulatory Focus, EMA Spokesman Martin Harvey said that the changes were geared at making the committees more efficient. "We have a lot of new legislation and changes coming through in the next year," Harvey said. "The new changes are about doing more with less while maintaining the Committee's workload. We are absolutely not saying that the committees are doing a bad job. They were designed a long time ago, and these changes are meant to improve their efficiency."
Still, the effects of the reorganization are expected to be both time- and resource-consuming. EMA's announcement notes that the process will involve "significant effort from scientific and support staff," and that EMA's ability to attend external meetings and forums will be strongly reduced through the first half of 2013.
In a statement, EMA Executive Director Guido Rasi apologized for the interruptions in staff availability, which is typically used to grant outside groups and regulatory professionals closer access to regulators.
"The aim of this exercise is to improve our processes and how best to use our resources, not least to ensure that we are better prepared for future legislative and policy challenges," Rasi said.
Tags: PRAC, Scientific Committees, CVMP, Reorganization, CHMP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.